Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

NMDA Antagonists as new Antidiabetics - Clinically tested compounds

20.02.2013
Diabetes mellitus is the most expensive chronic disorder, causing costs of about 40 billion Euros in 2010. More than 3/4 of these costs are associated with the treatment of subsequent disorders; chronic hyperglycaemia is deemed to be an independent risk factor for several severe health effects.

Therapy of type 2 diabetes aims at reducing the chronically increased glucose level in the blood as well as improving the existing insulin resistance. Oral antidiabetic drugs that have been currently available so far are problematic and not satisfactory in every respect. Blood glucose levels can be decreased in patients with manifested type 2 diabetes by administration of sulfonyl-urea/metformin or insulin. However, such treatment is associated with a high risk of hypoglycaemia. In addition, sulfonylureas are associated with an increased risk of mortality, in particular when combined with metformin. DPP-4 inhibitors have a low risk of hypoglycaemia, but merely lead to a slight improvement of the HbA1c-value compared to metformin. Further, there is no long-term evidence as to tolerability and mortality. Most long-term experiences are available for metformin. It is particularly effective in overweight diabetics and reduces diabetes complications and mortality by about 30%. However, monotherapy is typically effective only in the beginning of the treatment. Morphinan-derivatives have been known as medicaments for many years. The compounds have shown only minor adverse events upon long term administration and thus, are generally well tolerated.

It has now been surprisingly found that the morphinan-derivatives according to the invention increase the secretion of insulin only at elevated glucose concentrations in mouse and humans. If the glucose concentration is within the physiologically normal range, however, insulin secretion is not induced. Moreover, in type 2 diabetic mice, morphinans improve the viability of pancreatic beta cells that secrete insulin.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

info@technologieallianz.de | TechnologieAllianz e.V.
Further information:
http://www.technologieallianz.de/angebote.php?sort=sag&id=3037&lang=en
http://www.technologieallianz.de

More articles from Technology Offerings:

nachricht Highly specific nucleases for gene targeting and gene therapy
01.07.2015 | TechnologieAllianz e.V.

nachricht New Furin Inhibitors for Treatment of Infectious Diseases
01.07.2015 | TechnologieAllianz e.V.

All articles from Technology Offerings >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Viaducts with wind turbines, the new renewable energy source

Wind turbines could be installed under some of the biggest bridges on the road network to produce electricity. So it is confirmed by calculations carried out by a European researchers team, that have taken a viaduct in the Canary Islands as a reference. This concept could be applied in heavily built-up territories or natural areas with new constructions limitations.

The Juncal Viaduct, in Gran Canaria, has served as a reference for Spanish and British researchers to verify that the wind blowing between the pillars on this...

Im Focus: X-rays and electrons join forces to map catalytic reactions in real-time

New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions

A new technique pioneered at the U.S. Department of Energy's Brookhaven National Laboratory reveals atomic-scale changes during catalytic reactions in real...

Im Focus: Iron: A biological element?

Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.

Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...

Im Focus: Thousands of Droplets for Diagnostics

Researchers develop new method enabling DNA molecules to be counted in just 30 minutes

A team of scientists including PhD student Friedrich Schuler from the Laboratory of MEMS Applications at the Department of Microsystems Engineering (IMTEK) of...

Im Focus: Bionic eye clinical trial results show long-term safety, efficacy vision-restoring implant

Patients using Argus II experienced significant improvement in visual function and quality of life

The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Conference on Regenerative Medicine in Leipzig: Last chance to submit abstracts until 2 July

25.06.2015 | Event News

World Conference on Regenerative Medicine: Abstract Submission has been extended to 24 June

16.06.2015 | Event News

MUSE hosting Europe’s largest science communication conference

11.06.2015 | Event News

 
Latest News

Aluminum Clusters Shut Down Molecular Fuel Factory

06.07.2015 | Power and Electrical Engineering

Veja Mate Offshore orders 67 wind turbines including record long-term service

06.07.2015 | Press release

The quantum middle man

06.07.2015 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>